Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CRISPR | blindness
Previous Study | Return to List | Next Study

Single Ascending Dose Study in Participants With LCA10

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03872479
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : July 23, 2019
Sponsor:
Collaborator:
Editas Medicine, Inc.
Information provided by (Responsible Party):
Allergan

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of AGN-151587 (EDIT-101) administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").

Condition or disease Intervention/treatment Phase
Leber Congenital Amaurosis 10 Drug: AGN-151587 Phase 1 Phase 2

Detailed Description:
This is an open-label, single ascending dose study of AGN-151587 (EDIT-101) in adult and pediatric (ie, ages 3 to 17) participants with LCA10-IVS26. Approximately 18 participants will be enrolled in up to 5 cohorts to evaluate up to 3 dose levels of AGN-151587 in this study. AGN-151587 is a novel gene editing product designed to eliminate the mutation on the CEP290 gene that results in the retinal degeneration that defines LCA10-IVS26.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of AGN-151587 (EDIT-101) in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")
Estimated Study Start Date : July 31, 2019
Estimated Primary Completion Date : March 22, 2024
Estimated Study Completion Date : March 22, 2024


Arm Intervention/treatment
Experimental: Adults Low Dose
Single dose of AGN-151587 administered by subretinal injection surgery
Drug: AGN-151587
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Experimental: Adults Middle Dose
Single dose of AGN-151587 administered by subretinal injection surgery
Drug: AGN-151587
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Experimental: Adults High Dose
Single dose of AGN-151587 administered by subretinal injection surgery
Drug: AGN-151587
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Experimental: Pediatric Middle Dose
Single dose of AGN-151587 administered by subretinal injection surgery
Drug: AGN-151587
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Experimental: Pediatric High Dose
Single dose of AGN-151587 administered by subretinal injection surgery
Drug: AGN-151587
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.




Primary Outcome Measures :
  1. Frequency of Adverse Events related to AGN-151587 [ Time Frame: 1 year ]
  2. Number of participants experiencing procedural related adverse events [ Time Frame: 1 year ]
  3. Incidence of dose limiting toxicities [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Maximum tolerated dose as determined by occurrence of dose limiting toxicities [ Time Frame: 1 year ]
  2. Change from baseline in Mobility course score [ Time Frame: 1 year ]
    Testing the subjects visual function by having the subject walk through obstacle courses. Courses will have different levels of difficulty depending on the light levels of the room and the contrast of the objects in the room.

  3. Change from baseline in LogMAR measurement of BCVA [ Time Frame: 1 year ]
    The test will evaluate visual acuity in ranges from light perception to normal vision.

  4. Change from baseline in pupillary response [ Time Frame: 1 year ]
    Measuring the change in pupil diameter in response to a light stimulus.

  5. Change from baseline in dark adapted visual sensitivity using Full field light sensitivity threshold (FST) [ Time Frame: 1 year ]
    Flashes of light of varying luminance are presented to the eye and the subject reports is the flash was seen.

  6. Change from baseline in macula thickness [ Time Frame: 1 year ]
  7. Change from baseline in contrast sensitivity [ Time Frame: 1 year ]
    The Lea symbols chart will be used for subjects under age 6 and the Pelli-Robson chart for all other subjects. The images or letters on the charts are in decreasing contrast.

  8. Change from baseline in macular sensitivity as measured by microperimetry [ Time Frame: 1 year ]
    Visual field test measuring the amount of light perceived in specific parts of the macula.

  9. Change from baseline in color vision score using the Farnsworth 15 score [ Time Frame: 1 year ]
    The Farnsworth D15 tests for congenital and acquired color vision defects. Fifteen color discs will be arranged by the subject. Scoring is accomplished by recording the sequence selected by the patient on a copy of the score sheet. A patient with a color vision deficiency will arrange the color discs in a different order than a person with normal color vision.

  10. Change from baseline in QOL score for Age <8 years using the Children's Visual Function Questionnaire [ Time Frame: 1 year ]
  11. Change from baseline in QOL score for Age 8 to <18 years using the Impact of Vision Impairment for Children [ Time Frame: 1 year ]
  12. Change from baseline in QOL score for Age >18 years if BCVA is worse than 1.0 logMAR in both eyes using the Impact of Vision Impairment for Very Low Vision [ Time Frame: 1 year ]
  13. Change from baseline in QOL score for Age >18 years if BCVA is 1.0 logMAR or better in both eyes using the Impact of Vision Impairment [ Time Frame: 1 year ]
  14. Change from baseline in visual field using kinetic perimetry [ Time Frame: 1 year ]
    Kinetic perimetry looks as the visual field to identify regions of normal and abnormal sensitivity to light

  15. Change from baseline in Patient Global Impressions of Change score [ Time Frame: 1 year ]
    This QOL has 5 non-numeric choices for the subject to select how they believe their condition has changed.

  16. Change from baseline in gaze tracking [ Time Frame: 1 year ]
    Video clips of the eyes are used to measure eye position and stability over time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female
  • At least 3 years of age at screening with CEP290-related retinal degeneration caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in IVS26 of the CEP290 gene.
  • Best corrected visual acuity of light perception to 0.4 logMAR (20/50 Snellen equivalent).

Exclusion Criteria:

  • Other known disease-causing mutations
  • Achieves a passing score for the mobility course at the most difficult level
  • In either eye, active systemic or ocular/intraocular infection or inflammation
  • In either eye, history of steroid-responsive intraocular pressure with increases > 25 mm Hg following corticosteroid exposure
  • Any vaccination/immunization in the last 28 days before screening
  • Inability or unwillingness to take oral prednisone
  • Prior gene therapy or oligonucleotide treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03872479


Contacts
Layout table for location contacts
Contact: Clinical Trials Registry Team 1-877-277-8566 IR-CTRegistration@allergan.com

Locations
Layout table for location information
United States, Florida
Bascom Palmer Eye Institute Not yet recruiting
Miami, Florida, United States, 33136
United States, Massachusetts
Massachusetts Eye and Ear Infirmary Recruiting
Boston, Massachusetts, United States, 02114
United States, Michigan
W.K. Kellogg Eye Center - University of Michigan Not yet recruiting
Ann Arbor, Michigan, United States, 48105
United States, Oregon
Casey Eye Institute - OSHU Not yet recruiting
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Allergan
Editas Medicine, Inc.
Investigators
Layout table for investigator information
Study Director: Francisco Lopez, MD, PhD Allergan

Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT03872479     History of Changes
Other Study ID Numbers: 1991-201-008
First Posted: March 13, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Time Frame: After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.
Access Criteria: To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.
URL: http://www.allerganclinicaltrials.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Allergan:
CEP290
LCA10
Retinal degenerative diseases (RDD)
Leber congenital amaurosis (LCA)
CRISPR Treatment
LCA10-IVS26

Additional relevant MeSH terms:
Layout table for MeSH terms
Blindness
Leber Congenital Amaurosis
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms
Eye Diseases, Hereditary
Retinal Diseases